The expression and antigenicity of a truncated spike-nucleocapsid fusion protein of severe acute respiratory syndrome-associated coronavirus


In the absence of effective drugs, controlling SARS relies on the rapid identification of cases and appropriate management of the close contacts, or effective vaccines for SARS. Therefore, developing specific and sensitive laboratory tests for SARS as well as effective vaccines are necessary for national authorities.



Results: Genes encoding truncated nucleocapsid (N) and spike (S) proteins of SARSCoV were cloned into the expression vector pQE30 and fusionally expressed in Escherichia coli M15. The fusion protein was analyzed for reactivity with SARS patients' sera and with anti-sera against the two human coronaviruses HCoV 229E and HCoV OC43 by ELISA, IFA and immunoblot assays.

Furthermore, to evaluate the antigen-specific humoral antibody and T-cell responses in mice, the fusion protein was injected into 6-week-old BALB/c mice and a neutralization test as well as a T-cell analysis was performed. To evaluate the antiviral efficacy of immunization, BALB/c mice were challenged intranasally with SARSCoV at day 33 post injection and viral loads were determined by fluorescent quantitative RT-PCR.

Serological results showed that the diagnostic sensitivity and specificity of the truncated S-N fusion protein derived the SARS virus were >99 % (457/460) and 100.00 % (650/650), respectively. Furthermore there was no cross-reactivity with other two human coronaviruses.

High titers of antibodies to SRASCoV appeared in the immunized mice and the neutralization test showed that antibodies to the fusion protein could inhibit SARSCoV. The T cell proliferation showed that the fusion protein could induce an antigen-specific T-cell response.

Fluorescent quantitative RT-PCR showed that BALB/c mice challenged intranasally with SARSCoV at day 33 post injection were completely protected from virus replication.

Conclusion: The truncated S-N fusion protein is a suitable immunodiagnostic antigen and vaccine candidate.

Author: Feng Mu, Dongsheng Niu, Jingsong Mu, Bo He, Weiguo Han, Baoxing Fan, Shengyong Huang, Yan Qiu, Bo You and Weijun Chen
Credits/Source: BMC Microbiology 2008, 8:207



Published on: 2008-11-28



Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.

Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo



Comments Page 0 of 0
There are currently 0 comments to display.

 


+ Add New Comment


Custom Search

Username
Password










© 2012 7thSpace Interactive
All Rights Reserved - About | Disclaimer | Helpdesk
There are currently 71942 people browsing 7thSpace